Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine
Kala Pharmaceuticals, Inc. (KALA)
Last kala pharmaceuticals, inc. earnings: 2/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.kalarx.com
Company Research
Source: GlobeNewswire
ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA” or the “Company”) today celebrated the landmark Executive Order signed by U.S. President Donald J. Trump on April 18, 2026. The Order directs the FDA to prioritize the review of psychedelic compounds, instructs the DEA to reduce research restrictions, establishes expanded patient access pathways under the Right to Try Act, and allocates $50 million in federal funding to accelerate psychedelic therapy research, representing the most sweeping shift in U.S. federal psychedelic policy in decades. The Executive Order arrives at a pivotal moment, and KALA is uniquely and strategically positioned to capitalize on this seismic policy shift. KALA congratulates its client, Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light”), on this transformative federal policy shift. With expanded patient access pathways, reduced DEA research restrictions, and national priority review signals
Show less
Read more
Impact Snapshot
Event Time:
KALA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KALA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KALA alerts
High impacting Kala Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
KALA
News
- Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development OpportunitiesGlobeNewswire
- KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now LiveGlobeNewswire
- Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug CandidateGlobeNewswire
- Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution AcceleratesGlobeNewswire
- KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “ReseargencGlobeNewswire
KALA
Sec Filings
- 4/15/26 - Form 10-K
- 3/31/26 - Form NT
- 3/17/26 - Form D
- KALA's page on the SEC website